Citation Impact
Citing Papers
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
2015
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates
2017
Selective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
2011
Scoring functions for protein–protein interactions
2013 StandoutNobel
Engineering precision nanoparticles for drug delivery
2020 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Cancer Stem Cells
2006
Siglecs and their roles in the immune system
2007 Standout
The evolving role of natural products in drug discovery
2005 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Synthesis of Biomolecule‐Modified Mesoporous Silica Nanoparticles for Targeted Hydrophobic Drug Delivery to Cancer Cells
2011 StandoutNobel
Metabolomics methods for the synthetic biology of secondary metabolism
2012
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Gold nanoparticles in delivery applications☆
2008 Standout
Antibody-targeted drugs and drug resistance—Challenges and solutions
2014
Prodrug Strategies in Anticancer Chemotherapy
2007
Linker Technologies for Antibody–Drug Conjugates
2013
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Cancer Statistics, 2006
2006 Standout
A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma
2003
Drug development from marine natural products
2008 Standout
Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer
2007 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Potent antibody drug conjugates for cancer therapy
2009
Monoclonal antibody drug immunoconjugates for targeted treatment of cancer
2003
Antibody therapy of cancer
2012 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
The Molecular Basis of Leukemia
2004
Monoclonal antibody therapeutics: history and future
2012
Environmentally responsive peptides as anticancer drug carriers☆
2009
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
2014
Bioactivity‐Guided Genome Mining Reveals the Lomaiviticin Biosynthetic Gene Cluster in Salinispora tropica
2013
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Antibody–drug conjugates: targeted drug delivery for cancer
2010
Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice
2013
Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
2003
Antibody–drug conjugates: current status and future directions
2013
Natural products and Pharma 2011: Strategic changes spur new opportunities
2011
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
2005
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Folate-targeted chemotherapy
2004
Mechanisms controlling pathogenesis and survival of leukemic stem cells
2004
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
2012 StandoutNobel
A Bioorthogonal Reaction of N‐Oxide and Boron Reagents
2015 StandoutNobel
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
2002
Antibody–cytotoxic agent conjugates for cancer therapy
2005
Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
2005
Antibody‐Drug Conjugates for the Treatment of Cancer
2012
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities
2003
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
2014
Arming antibodies: prospects and challenges for immunoconjugates
2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
2005
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
2003
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
2003
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
2004
Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies
2005
Antibody–Drug Conjugates for Tumor Targeting—Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins
2015
Advances in Microfluidic Materials, Functions, Integration, and Applications
2013
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Lessons Learned from Marketed and Investigational Prodrugs
2004
Acute Myeloid Leukemia
2015 Standout
Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting
2019
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
2019
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
2011 Standout
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Electrochemical Detection for Paper-Based Microfluidics
2009
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells
2007 Standout
Herceptin-Geldanamycin Immunoconjugates
2004
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin–induced cytotoxicity
2004
Stretchable and Soft Electronics using Liquid Metals
2017 Standout
Antibody Conjugates: From Heterogeneous Populations to Defined Reagents
2015
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Diagnostics for the Developing World: Microfluidic Paper-Based Analytical Devices
2009 Standout
Gemtuzumab ozogamicin for acute myeloid leukemia
2017
Antibody therapy for acute myeloid leukaemia
2013
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
2003
Recent Advances in Stretchable and Transparent Electronic Materials
2016
Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193- N -Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts
2004
Antibody-Drug Conjugates in Cancer Therapy
2012
Natural product and natural product derived drugs in clinical trials
2014 Standout
Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs
2006
In vivoDrug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
2005
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Soft Robotic Grippers
2018 Standout
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
2004
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Sensitive ELISA Method for the Measurement of Catabolites of Antibody–Drug Conjugates (ADCs) in Target Cancer Cells
2015
Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy
2014
Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
2003
Oxime Ligation on the Surface of Mesoporous Silica Nanoparticles
2015 StandoutNobel
A cell nanoinjector based on carbon nanotubes
2007 StandoutNobel
Emerging Droplet Microfluidics
2017 Standout
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
2003
Works of Ryan E. Holcomb being referenced
Electrode array detector for microchip capillary electrophoresis
2008
Review: Microfluidic applications in metabolomics and metabolic profiling
2009
Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia
2001